南方医科大学学报
南方醫科大學學報
남방의과대학학보
JOURNAL OF SOUTHERN MEDICAL UNIVERSITY
2014年
5期
731-735
,共5页
吴蓉%吴小翎%刘波%张伟%高静%肖晓秋%张霞
吳蓉%吳小翎%劉波%張偉%高靜%肖曉鞦%張霞
오용%오소령%류파%장위%고정%초효추%장하
非酒精性脂肪性肝炎%普罗布考%法尼醇X受体%固醇调节元件结合蛋白1c
非酒精性脂肪性肝炎%普囉佈攷%法尼醇X受體%固醇調節元件結閤蛋白1c
비주정성지방성간염%보라포고%법니순X수체%고순조절원건결합단백1c
non-alcoholic steatohepatitis%probucol%farnesoid X receptor%SREBP-1C
目的:探讨降脂药物普罗布考对非酒精性脂肪性肝炎大鼠肝脏病理、血清学指标的改善作用、对肝脏胆汁酸受体FXR及下游基因、蛋白SHP、SREBP-1C表达的影响。方法雄性SD大鼠40只,随机平均分4组:(1)正常对照组,予普通饲料;(2)高脂组,予高脂饲料;(3)普罗布考对照组,予普通饲料及普罗布考灌胃(500 mg/kg· d-1);(4)普罗布考干预组,予高脂饲料及普罗布考灌胃(500 mg/kg· d-1)。15周后处死,检测各组大鼠血清转氨酶、血脂、胆汁酸,同时取肝组织,切片行HE染色及病理评分;RT-PCR及Western Blot的方法检测肝组织FXR、SHP及SREBP-1C基因及蛋白的表达水平。结果与高脂组比较,普罗布考干预组肝脏脂肪变性及炎症浸润程度明显减轻,血清ALT(126.40±52.56 vs 80.18±22.90 U/L,P<0.01)、AST(250.40±30.45 vs 179.45±41.14 U/L,P<0.01)及胆固醇(2.7±0.2 vs 2.4±0.3 mmol/L,P<0.01)、游离脂肪酸(0.734±.0.11 vs 0.557±0.19 mmol/L,P<0.05),胆汁酸(48.3±11.6 vs 24.9±17.7μmol/L,P<0.01)的水平显著降低;FXR、SHP mRNA及蛋白表达水平显著上升(P<0.05),SREBP-1C mRNA及蛋白表达则显著降低(P<0.05)。结论普罗布考改善NASH大鼠肝功及肝脏脂肪变性的作用与上调胆汁酸受体FXR的表达水平有关。
目的:探討降脂藥物普囉佈攷對非酒精性脂肪性肝炎大鼠肝髒病理、血清學指標的改善作用、對肝髒膽汁痠受體FXR及下遊基因、蛋白SHP、SREBP-1C錶達的影響。方法雄性SD大鼠40隻,隨機平均分4組:(1)正常對照組,予普通飼料;(2)高脂組,予高脂飼料;(3)普囉佈攷對照組,予普通飼料及普囉佈攷灌胃(500 mg/kg· d-1);(4)普囉佈攷榦預組,予高脂飼料及普囉佈攷灌胃(500 mg/kg· d-1)。15週後處死,檢測各組大鼠血清轉氨酶、血脂、膽汁痠,同時取肝組織,切片行HE染色及病理評分;RT-PCR及Western Blot的方法檢測肝組織FXR、SHP及SREBP-1C基因及蛋白的錶達水平。結果與高脂組比較,普囉佈攷榦預組肝髒脂肪變性及炎癥浸潤程度明顯減輕,血清ALT(126.40±52.56 vs 80.18±22.90 U/L,P<0.01)、AST(250.40±30.45 vs 179.45±41.14 U/L,P<0.01)及膽固醇(2.7±0.2 vs 2.4±0.3 mmol/L,P<0.01)、遊離脂肪痠(0.734±.0.11 vs 0.557±0.19 mmol/L,P<0.05),膽汁痠(48.3±11.6 vs 24.9±17.7μmol/L,P<0.01)的水平顯著降低;FXR、SHP mRNA及蛋白錶達水平顯著上升(P<0.05),SREBP-1C mRNA及蛋白錶達則顯著降低(P<0.05)。結論普囉佈攷改善NASH大鼠肝功及肝髒脂肪變性的作用與上調膽汁痠受體FXR的錶達水平有關。
목적:탐토강지약물보라포고대비주정성지방성간염대서간장병리、혈청학지표적개선작용、대간장담즙산수체FXR급하유기인、단백SHP、SREBP-1C표체적영향。방법웅성SD대서40지,수궤평균분4조:(1)정상대조조,여보통사료;(2)고지조,여고지사료;(3)보라포고대조조,여보통사료급보라포고관위(500 mg/kg· d-1);(4)보라포고간예조,여고지사료급보라포고관위(500 mg/kg· d-1)。15주후처사,검측각조대서혈청전안매、혈지、담즙산,동시취간조직,절편행HE염색급병리평분;RT-PCR급Western Blot적방법검측간조직FXR、SHP급SREBP-1C기인급단백적표체수평。결과여고지조비교,보라포고간예조간장지방변성급염증침윤정도명현감경,혈청ALT(126.40±52.56 vs 80.18±22.90 U/L,P<0.01)、AST(250.40±30.45 vs 179.45±41.14 U/L,P<0.01)급담고순(2.7±0.2 vs 2.4±0.3 mmol/L,P<0.01)、유리지방산(0.734±.0.11 vs 0.557±0.19 mmol/L,P<0.05),담즙산(48.3±11.6 vs 24.9±17.7μmol/L,P<0.01)적수평현저강저;FXR、SHP mRNA급단백표체수평현저상승(P<0.05),SREBP-1C mRNA급단백표체칙현저강저(P<0.05)。결론보라포고개선NASH대서간공급간장지방변성적작용여상조담즙산수체FXR적표체수평유관。
Objective To determine the effects of probucol on serum parameters and liver histopathology in rats with non-alcoholic steatohepatitis (NASH) and explore the mechanisms. Methods Forty male Sprague-Dawley rats were randomly assigned into 4 equal groups, namely the normal control group (NC group) with a standard feeding, high-fat diet group (HD group) fed with a high-fat diet, probucol (500 mg/kg daily) control group (NP group) fed with standard diet, and probucol group fed with a high-fat diet (HP group). After 15 weeks of feeding, the rats were euthanized for histopathological inspection of the liver with HE staining and detection of farnesoid X receptor (FXR), SHP and SREBP-1C expressions using semi-quantitative RT-PCR and Western blotting. Results After the 15-week feeding, the rats in HP group had significantly lower levels of serum ALT, AST, cholesterol, bile acid, and free fatty acid than those in HD group (P<0.01 or 0.05). Compared with the normal control group, high-fat diet feeding resulted in significantly decreased mRNA and protein levels of FXR and SHP (P<0.05) and significantly increased SREBP-1C level (P<0.05). These high-fat diet-induced gene expression changes were reversed by probucol intervention (P<0.05). Conclusion Probucol treatment has beneficial effects on serum parameters, hepatic steatosis, and lobular inflammation in high-fat diet-induced NASH possibly by up-regulating FXR expression.